Translational proteomics: what can you do for true patients?
Matching the right medical strategy to the right patient is the key for modern clinical oncology. To this aim, we have many delicate drugs designed to target in elegant ways critical proteins identified in cancer cells. However, clinical oncologists and multidisciplinary groups devoted to treating patients in an integrative fashion have histology and an TNM staging system as the most relevant biomarkers to decide therapeutic approaches for our patients. In addition, the most used drugs are classical chemotherapeutic compounds such as cisplatin, epirrubicin, irinotecan, oxaliplatin, and so on. Thus, new targeted therapies, surgery, radiotherapy, and chemotherapy will live together causing a duality for the immediate future. We will try to delineate unmet needs for clinical oncologists that would add value for cancer proteomics in terms of true patients.
Biomarkers and Experimental Therapeutics for Cancer Group, IdiPAZ, University Hospital La Paz, Madrid, Spain. cbelda.hulp@salud.madrid.org
Cristobal
C
Belda-Iniesta
Javier
J
de Castro
Rosario
R
Perona
D015415:Biomarkers; D019937:Diagnostic Techniques and Procedures; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D009369:Neoplasms; D057285:Precision Medicine / Q000379:methods*; D040901:Proteomics / Q000379:methods*
D015415:Biomarkers